Gastroenterology · 1 h ago
Chinese consensus outlines diagnosis and management of pancreatic portal hypertension
A Chinese Society of Gastroenterology expert panel developed a consensus on pancreatic portal hypertension (PPH), a condition associated with pancreatic disease or surgery. After reviewing available evidence and completing three Delphi rounds, the panel formulated 19 statements on its causes, diagnosis, treatment and prognosis.
- Expert panel completed three Delphi rounds.
- Consensus comprises 19 statements on PPH.
- Statements cover diagnosis, treatment and prognosis.
Pancreatic portal hypertension (PPH) is a form of portal hypertension associated with pancreatic diseases or surgery. Its presentation may be insidious, while complications including splenomegaly and upper gastrointestinal bleeding can occur at advanced stages. The consensus authors note that wider use of advanced imaging and endoscopy has increased PPH detection, but that management strategies had not previously been comprehensively summarized.
The Chinese Society of Gastroenterology of the Chinese Medical Association convened an expert panel to review available evidence on causes, risk factors, clinical manifestations, diagnosis, therapy and prognostic assessment. Following three rounds of Delphi questionnaires and voting, the panel formulated 19 consensus statements intended to guide PPH diagnosis and management. The source summary does not provide the individual statements or details of the evidence supporting them, so their specific recommendations and strength cannot be assessed here.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
BMC Medicine: Chinese consensus on the management of pancreatic portal hypertension ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.